Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,847 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,849 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03428529 | Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.(INCAGI004) | completed | Phase 2 / Phase 3 | 63 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 0 | Feb 9, 2018 | clinicaltrials |
| NCT02026583 | A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients | completed | Phase 2 | 43 | Samsung Medical CenterOTHER | 1 | Jan 17, 2018 |
| clinicaltrials |
| NCT01676714 | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | completed | Phase 2 | 10 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00801294 | A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer | completed | Phase 2 | 46 | Boehringer IngelheimINDUSTRY | 1 | Dec 29, 2017 | clinicaltrials |
| NCT02271464 | Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer(MOMA) | completed | Phase 2 | 232 | Azienda Ospedaliero, Universitaria PisanaOTHER | 1 | Dec 7, 2017 | clinicaltrials |
| NCT01149304 | Preventive Effect of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid to Radiation Induced Liver Toxicity(ELDORADO) | completed | Phase 2 | 22 | University of MagdeburgOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01139138 | Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer(PIE) | completed | Phase 1 / Phase 2 | 49 | The Queen Elizabeth HospitalOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02316028 | Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)(DECIT) | completed | Phase 1 / Phase 2 | 11 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00972881 | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer(EXCITE) | completed | Phase 1 / Phase 2 | 82 | University College, LondonOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02129257 | Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer(AMALTHEA) | completed | Phase 2 | 73 | Hellenic Cooperative Oncology GroupOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | completed | Phase 1 / Phase 2 | 20 | Array BioPharmaINDUSTRY | 10 | Oct 9, 2017 | clinicaltrials |
| NCT00682786 | Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma | completed | Phase 2 | 135 | Washington University School of MedicineOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00309179 | A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors | completed | Phase 2 | 41 | Eisai Inc.INDUSTRY | 2 | Sep 14, 2017 | clinicaltrials |
| NCT02280811 | T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Sep 6, 2017 | clinicaltrials |
| NCT00847119 | Xeloda and Bevacizumab to Treat Rectal Cancer(xeberecto) | completed | Phase 2 | 43 | Institut Català d'OncologiaOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01623206 | Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding | completed | Phase 2 | 30 | Laboratorio Elea Phoenix S.A.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01333709 | Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma(GRECCAR4) | completed | Phase 2 | 150 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Aug 21, 2017 | clinicaltrials |
| NCT00865189 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer(INOVA) | completed | Phase 2 | 91 | Hoffmann-La RocheINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01040000 | QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer | completed | Phase 1 / Phase 2 | 94 | Precision Biologics, IncINDUSTRY | 1 | Aug 4, 2017 | clinicaltrials |
| NCT01836653 | Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases(ATOM) | completed | Phase 2 | 122 | EPS CorporationOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00875771 | Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients(AVAXIRI) | completed | Phase 2 | 80 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00885885 | Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases(PLANET) | completed | Phase 2 | 80 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01704703 | Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques(ULTRA) | completed | Phase 2 | 72 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01875380 | Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer(REFRAME) | completed | Phase 2 | 46 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00326495 | BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2017 | clinicaltrials |
| NCT01013805 | Preoperative Radiotherapy and Chemotherapy in Patients With Locally Advanced Rectal Cancer(PROArCT) | completed | Phase 2 | 41 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01807546 | Oral Rigosertib for Squamous Cell Carcinoma | completed | Phase 2 | 64 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02223078 | Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.(CC4) | completed | Phase 2 | — | Cancer Advances Inc.INDUSTRY | 1 | Jun 20, 2017 | clinicaltrials |
| NCT02246049 | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC(QUATTRO) | completed | Phase 2 | 69 | EPS CorporationOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00582660 | Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib(UAB0040) | completed | Phase 2 | 40 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2017 | clinicaltrials |
| NCT01383707 | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer | completed | Phase 2 | 77 | Hoffmann-La RocheINDUSTRY | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00381862 | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT00636610 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | completed | Phase 2 | 199 | Genentech, Inc.INDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00468910 | Aspirin in Preventing Colorectal Cancer in Patients at Increased Risk of Colorectal Cancer | completed | Phase 2 | 79 | National Cancer Institute (NCI)NIH | 1 | May 31, 2017 | clinicaltrials |
| NCT01418222 | FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 194 | Genentech, Inc.INDUSTRY | 1 | May 30, 2017 | clinicaltrials |
| NCT02219893 | Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial(ImmunoPeCa) | completed | Phase 1 / Phase 2 | 15 | Oslo University HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00842257 | Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT03146377 | Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer | completed | Phase 2 | 32 | The University of Hong KongOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01051167 | Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer(CEBIFOX) | completed | Phase 2 | 59 | Martin Schuler, Prof. Dr. med.OTHER | 1 | May 8, 2017 | clinicaltrials |
| NCT00004005 | Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin | completed | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01722162 | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | completed | Phase 2 | 47 | Washington University School of MedicineOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00828984 | Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00030563 | Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver | completed | Phase 2 | — | University of WashingtonOTHER | 2 | Apr 17, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT01273051 | Transanal Endoscopic Microsurgery (TEM) After Radiochemotherapy for Rectal Cancer(CARTS) | completed | Phase 2 | 55 | Radboud University Medical CenterOTHER | 1 | Apr 14, 2017 | clinicaltrials |
| NCT00002842 | Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer | completed | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT01292356 | Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response | completed | Phase 2 | 28 | Poitiers University HospitalOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01047293 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 47 | University of UtahOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01523431 | Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients | completed | Phase 2 / Phase 3 | 583 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Mar 30, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Feb 9, 2018source: clinicaltrials